title: Hypothermia in the sepsis syndrome and clinical outcome. The Methylprednisolone Severe Sepsis Study Group.
abstract: OBJECTIVE
  To evaluate the consequences of clinical hypothermia associated with sepsis syndrome and septic shock.
  
  
  METHODS
  Analysis of data from a multi-institutional, randomized, placebo-controlled, prospective study with predetermined end-point analysis of development of shock, recovery from shock, hospital length of stay, and death.
  
  
  METHODS
  Multi-institutional medical and surgical ICUs.
  
  
  METHODS
  Patients meeting predetermined criteria for severe sepsis syndrome.
  
  
  METHODS
  Appropriate sepsis and shock care with 50% of patients receiving methylprednisolone and 50% receiving placebo.
  
  
  RESULTS
  The occurrence rate of hypothermia (< 35.5 degrees C) is 9% in this population. When compared with febrile patients, hypothermic patients had a higher frequency of central nervous system dysfunction (88% vs. 60%), increased serum bilirubin concentration (35% vs. 15%), prolonged prothrombin times (50% vs. 23%), shock (94% vs. 61%), failure to recover from shock (66% vs. 26%), and death (62% vs. 26%). The hypothermic patients were also more likely to be classified as having a rapidly or ultimately fatal disease upon study admission.
  
  
  CONCLUSIONS
  This prospective study confirms that hypothermia associated with sepsis syndrome has a significant relationship to outcome manifest by increased frequency of shock and death from shock. This finding is in sharp contrast to the protective effects of induced hypothermia in septic animals and perhaps man.
authors.affiliation: Division of Critical Care Medicine, LDS Hospital, Salt Lake City, UT.
authors.forename: T P
authors.initials: TP
authors.lastname: Clemmer
authors.forename: C J
authors.initials: CJ
authors.lastname: Fisher
authors.forename: R C
authors.initials: RC
authors.lastname: Bone
authors.forename: G J
authors.initials: GJ
authors.lastname: Slotman
authors.forename: C A
authors.initials: CA
authors.lastname: Metz
authors.forename: F O
authors.initials: FO
authors.lastname: Thomas
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001663:Bilirubin / Q000097:blood; D005334:Fever / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007035:Hypothermia / Q000209:etiology / Q000401:mortality* / Q000503:physiopathology; D007362:Intensive Care Units; D007902:Length of Stay / Q000706:statistics & numerical data; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D011517:Prothrombin Time; D012307:Risk Factors; D018805:Sepsis / Q000150:complications* / Q000188:drug therapy; D012772:Shock, Septic / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D001663:Bilirubin; D008775:Methylprednisolone